# T1DM Immunotherapy Using Polyclonal Tregs + IL-2

> **NCT02772679** · PHASE1 · COMPLETED · sponsor: **Jeffrey Bluestone** · enrollment: 16 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **BIOLOGICAL:** PolyTregs+IL-2

## Key facts

- **NCT ID:** NCT02772679
- **Lead sponsor:** Jeffrey Bluestone
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2021-08-27
- **Final completion:** 2021-08-27
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2021-10-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02772679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02772679, "T1DM Immunotherapy Using Polyclonal Tregs + IL-2". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02772679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*